Tyra Biosciences (NASDAQ:TYRA) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a report published on Monday,Benzinga reports. They currently have a $30.00 target price on the stock.

Several other equities research analysts have also recently weighed in on TYRA. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Friday. UBS Group assumed coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tyra Biosciences has a consensus rating of “Buy” and a consensus target price of $30.83.

Tyra Biosciences Price Performance

Shares of NASDAQ:TYRA opened at $9.30 on Monday. The business has a 50 day simple moving average of $12.32 and a two-hundred day simple moving average of $16.22. Tyra Biosciences has a 1 year low of $9.05 and a 1 year high of $29.60. The firm has a market capitalization of $470.61 million, a PE ratio of -5.78 and a beta of 1.09.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.05. Equities research analysts expect that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Insider Activity

In other Tyra Biosciences news, Director Nina S. Kjellson sold 3,993 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $16.36, for a total transaction of $65,325.48. Following the transaction, the director now owns 3,707,420 shares in the company, valued at approximately $60,653,391.20. This represents a 0.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 21,998 shares of company stock worth $344,818. Insiders own 15.40% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

A number of large investors have recently made changes to their positions in TYRA. Janus Henderson Group PLC acquired a new position in shares of Tyra Biosciences in the third quarter valued at about $24,994,000. Rhumbline Advisers increased its holdings in Tyra Biosciences by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock worth $364,000 after buying an additional 1,027 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Tyra Biosciences during the 3rd quarter worth approximately $593,000. Barclays PLC lifted its stake in Tyra Biosciences by 200.5% during the 3rd quarter. Barclays PLC now owns 37,625 shares of the company’s stock valued at $884,000 after acquiring an additional 25,106 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Tyra Biosciences by 1.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock valued at $8,667,000 after buying an additional 3,896 shares during the last quarter. 84.14% of the stock is owned by hedge funds and other institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.